Tuotekehitysputki

Kehitysputkessa olevat hoidot

Tutkimus- ja kehitysryhmiemme tavoitteena on löytää aivosairauksien taustalla olevat mekanismit. Kuljemme yhdessä kohti tavoitetta kehittää ja tarjota uusia hoitomuotoja, jotka edistävät potilaiden hoidon standardeja sekä osoittavat ne aivosairauksien alueet, joissa on suurimmat kehitystarpeet.

Hormonal / neuropeptide signaling


Projekti	Alue
Eptinezumab (anti-CGRP mAb)¹	Migraine prevention²	Filing
Eptinezumab (anti-CGRP mAb)¹	Cluster headache	3
Lu AG09222 (anti-PACAP mAb)³	Migraine prevention²	2
Lu AG13909 (anti-ACTH mAb)⁴	Neurohormonal dysfunctions	1

Circuitry / neuronal biology


Projekti	Alue
Brexpiprazole⁵	PTSD⁶	Filing
Lu AF28996 (D1-D2 agonist)⁷	Parkinson's disease	1
MAGLi program⁸	Neurology	1
Bexicaserin (5HT2C agonist)	Developmental and epileptic encephalopathies	3

Protein aggregation, folding and clearance


Projekti	Alue	Faasi I	Faasi II	Faasi III
Amlenetug (anti α-synuclein mAb)	Synucleinopathies (MSA)				3

Neuroinflammation / Neuroimmunology


Projekti	Alue	Faasi I	Faasi II	Faasi III
Lu AG22515 (CD40L blocker)⁹	Neurology				1

CGRP: Calcitonin gene-related peptide;
Two phase III clinical trials, supporting registration in Asia, including China and Japan: SUNRISE, and SUNSET trials.
PACAP: Pituitary adenylate cyclase activating peptide;
ACTH: Adrenocorticotropic hormone. Two phase Ib trials are currently ongoing in Congenital Adrenal Hyperplasia and Cushing’s Disease. For technical reasons, the latter has been officially categorized as a Phase II trial to adhere to local requirements in Georgia;
Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors;
Post-traumatic stress disorder;
Dopamine receptor D1 and D2;
MAGLi: Monoacylglycerol lipase (“MAGlipase”) inhibitor;
Ph1b trial ongoing in TED (Thyroid Eye Disease)